A 2524440

Drug Profile

A 2524440

Latest Information Update: 24 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; ICOS Corporation
  • Class
  • Mechanism of Action E-selectin inhibitors; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 15 May 2001 Discontinued-Preclinical for Inflammation in USA (PO)
  • 15 Sep 1999 Preclinical development for Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top